Fluorodopa (18F)
Chemical compound
From Wikipedia, the free encyclopedia
Fluorodopa (18F), also known as FDOPA, is a fluorinated form of L-DOPA primarily synthesized as its fluorine-18 isotopologue for use as a radiotracer in positron emission tomography (PET).[2]
| |
| Clinical data | |
|---|---|
| Trade names | Fluorodopa F18 |
| Other names | 6-fluoro-L-DOPA, FDOPA |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| License data |
|
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C9H10FNO4 |
| Molar mass | 215.180 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
The most common side effects are injection site pain.[1]
Medical uses
Fluorodopa (18F) is indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adults with suspected Parkinsonian syndromes.[1]
History
In October 2019, Fluorodopa (18F) was approved in the United States for the visual detection of certain nerve cells in adults with suspected Parkinsonian syndromes.[3][4]
The US Food and Drug Administration approved Fluorodopa F 18 based on evidence from one clinical trial of 56 participants with suspected Parkinsonian syndromes.[3] The trial was conducted at one clinical site in the United States.[3]
